<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1274">
  <stage>Registered</stage>
  <submitdate>28/08/2006</submitdate>
  <approvaldate>28/08/2006</approvaldate>
  <nctid>NCT00370084</nctid>
  <trial_identification>
    <studytitle>Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia</studytitle>
    <scientifictitle>Effects of Itopride Hydrochloride on Gastric Emptying, Glycaemia and "Meal-related" Symptoms in Patients With Type 1 and Type 2 Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>041026</secondaryid>
    <secondaryid>ITODG04-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastroparesis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Itopride
Other interventions - Placebo

Placebo Comparator: Placebo - 

Experimental: Itopride - 


Treatment: drugs: Itopride
oral, three times daily

Other interventions: Placebo
oral, three times daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Gastric emptying assessment</outcome>
      <timepoint>weekly</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Glycemia, relief of upper gastrointestinal symptoms, intragastric meal distribution</outcome>
      <timepoint>weekly</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type-1 and Type-2 diabetic patients

          -  18 to 65 years old

          -  Glycated haemoglobin level (HbA1c) below 9%

          -  Body mass index (BMI) between 18 and 35 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Use of medications potentially influencing upper gastrointestinal motility or appetite
             within one week of the study (e.g. prokinetic drugs, macrolide antibiotics)

          -  Exposure to radiation for research purposes during the previous 12 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>University of Adelaide, Department of Medicine - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Forest Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Itopride is a new compound that is already marketed in Japan and in some countries of Eastern
      Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.
      Due to inadequate gastric emptying, these patients often have symptoms of bloating, nausea
      and vomiting following ingestion of a meal. The goal of this study is to evaluate the effects
      of Itopride on gastric motor function and glycemia in patients with diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00370084</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Horowitz, M.D.</name>
      <address>Royal Adelaide Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>